Cytek Biosciences Reports Third Quarter 2025 Financial Results
Cytek Biosciences (NASDAQ: CTKB) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $52.3M, up 2% year-over-year, with total installed base at 3,456 instruments (added 161 units). Total recurring revenue rose 19% and revenue from biotech/pharma/CRO customers grew 14%. GAAP gross profit was $27.6M and GAAP gross margin was 53% (adjusted gross margin 55% vs 60% prior year). Operating expenses increased 10% and G&A rose 47% due to litigation-related costs and a $0.7M one-time write-off. Net loss was $5.5M versus net income of $0.9M in Q3 2024. Adjusted EBITDA was $2.5M. Cash and marketable securities totaled $261.7M. Full‑year 2025 revenue guidance reaffirmed at $196M–$205M.
Cytek Biosciences (NASDAQ: CTKB) ha riportato i risultati del terzo trimestre 2025 per il periodo terminato il 30 settembre 2025. Le entrate sono state 52,3 milioni di dollari, in aumento del 2% su base annua, con una base installata totale di 3.456 strumenti (aggiunti 161 unità). Ricavi ricorrenti totali sono aumentati del 19% e i ricavi dai clienti biotech/pharma/CRO sono cresciuti del 14%. Il utile lordo GAAP è stato 27,6 milioni di dollari e il margine lordo GAAP è stato 53% (margine lordo rettificato 55% contro 60% dell’anno precedente). Le spese operative sono aumentate del 10% e G&A è salita del 47% a causa di costi legati a contenziosi e di una svalutazione una tantum di 0,7 milioni di dollari. La perdita netta è stata 5,5 milioni di dollari rispetto a un utile di 0,9 milioni di dollari nel Q3 2024. L’EBITDA rettificato è stato 2,5 milioni di dollari. Le disponibilità liquide e titoli negoziabili ammontavano a 261,7 milioni di dollari. Le guidance di fatturato per l’intero 2025 sono state riaffermate a 196–205 milioni di dollari.
Cytek Biosciences (NASDAQ: CTKB) informó los resultados del tercer trimestre de 2025 para el periodo que terminó el 30 de septiembre de 2025. Los ingresos fueron 52,3 millones de dólares, con un aumento del 2% interanual, con una base instalada total de 3.456 instrumentos (se añadieron 161 unidades). Los ingresos recurrentes totales subieron un 19% y los ingresos de clientes de biotecnología/farmacéutica/CRO crecieron un 14%. El beneficio bruto GAAP fue 27,6 millones de dólares y el margen bruto GAAP fue 53% (margen bruto ajustado 55% frente al 60% del año anterior). Los gastos operativos aumentaron un 10% y G&A subió un 47% debido a costos relacionados con litigios y a una amortización única de 0,7 millones de dólares. La pérdida neta fue de 5,5 millones de dólares frente a un ingreso neto de 0,9 millones de dólares en el Q3 de 2024. El EBITDA ajustado fue de 2,5 millones de dólares. El efectivo y valores negociables sumaron 261,7 millones de dólares. Las previsiones de ingresos para 2025 se reiteraron en 196–205 millones de dólares.
Cytek Biosciences (NASDAQ: CTKB)는 2025년 9월 30일자로 종료된 2025년 3분기 실적을 발표했습니다. 매출은 $52.3M으로 전년 대비 2% 증가했고, 설치 기반은 3,456대로 늘었으며 161대가 추가되었습니다. 총 반복 매출은 19% 증가했고 바이오/제약/CRO 고객으로부터의 매출은 14% 증가했습니다. GAAP 총이익은 $27.6M, GAAP 총이익률은 53%였고 조정된 총이익률은 55%로 전년의 60%에 비해 낮았습니다. 영업비용은 10% 증가했고 일반관리비는 소송 관련 비용과 일회성 차손실로 47% 올랐습니다. 순손실은 $5.5M였으며 2024년 3분기 순이익은 $0.9M였습니다. 조정된 EBITDA는 $2.5M였습니다. 현금 및 시장성 있는 증권은 총 $261.7M이었습니다. 2025년 연간 매출 가이던스는 $196M–$205M로 재확인되었습니다.
Cytek Biosciences (NASDAQ: CTKB) a publié les résultats du troisième trimestre 2025 pour la période se terminant le 30 septembre 2025. Le chiffre d’affaires s’est élevé à 52,3 millions de dollars, en hausse de 2% sur un an, avec une base installée totale de 3 456 instruments (ajout de 161 unités). Les revenus récurrents totaux ont augmenté de 19% et les revenus des clients biotech/pharma/CRO ont crû de 14%. Le bénéfice brut GAAP était de 27,6 millions de dollars et la marge brute GAAP de 53% (marge brute ajustée de 55% contre 60% l’année précédente). Les dépenses opérationnelles ont augmenté de 10% et les frais G&A de 47% en raison de coûts liés à des litiges et d’une écriture d’actifs de 0,7 million de dollars exceptionnelle. La perte nette était de 5,5 millions de dollars contre un bénéfice net de 0,9 million de dollars au T3 2024. L’EBITDA ajusté était de 2,5 millions de dollars. La trésorerie et les valeurs mobilières de négociation s’élevaient à 261,7 millions de dollars. Les prévisions de chiffre d’affaires pour l’ensemble de 2025 ont été réaffirmées à 196–205 millions de dollars.
Cytek Biosciences (NASDAQ: CTKB) meldete die Ergebnisse des dritten Quartals 2025 für den Zeitraum zum 30. September 2025. Umsatz betrug 52,3 Mio. USD, ein Anstieg von 2% gegenüber dem Vorjahr, mit einer gesamten installierten Basis von 3.456 Instrumenten (Hinzufügung von 161 Einheiten). Alle wiederkehrenden Umsätze stiegen um 19% und Einnahmen von Biotech/Pharma/CRO-Kunden wuchsen um 14%. GAAP Rohertrag war 27,6 Mio. USD und GAAP-Bruttomarge 53% (bereinigte Bruttomarge 55% gegenüber 60% im Vorjahr). Betriebsausgaben stiegen um 10% und G&A stieg um 47% aufgrund litigation-bezogener Kosten und einer einmaligen Abschreibung von 0,7 Mio. USD. Nettoloss betrug 5,5 Mio. USD gegenüber einem Nettogewinn von 0,9 Mio. USD im Q3 2024. Bereinigtes EBITDA betrug 2,5 Mio. USD. Bargeld und marktgängige Wertpapiere beliefen sich auf 261,7 Mio. USD. Die Umsatzprognose für das Gesamtjahr 2025 wurde bei 196–205 Mio. USD bestätigt.
Cytek Biosciences (NASDAQ: CTKB) أبلغت عن نتائج الربع الثالث من عام 2025 للفترة المنتهية في 30 سبتمبر 2025. الإيرادات كانت $52.3M، بارتفاع قدره 2% على أساس سنوي، مع قاعدة مركبة إجمالية تبلغ 3,456 جهازاً (تمت إضافة 161 وحدة). الإيرادات المتكررة الإجمالية ارتفعت بنسبة 19% وإيرادات عملاء التكنولوجيا الحيوية/الأدوية/أنظمة الاختبار المتعاقدة ارتفعت بنسبة 14%. الربح الإجمالي وفق معايير GAAP كان $27.6M وهو الهامش الإجمالي GAAP 53% (الهامش الإجمالي المعدل 55% مقابل 60% في العام السابق). زادت المصروفات التشغيلية بنسبة 10% وارتفعت المصروفات العامة والإدارية بنسبة 47% بسبب تكاليف مرتبطة بالدعاوى وخسارة ائتمانية لمرة واحدة قدرها $0.7M. صافي الخسارة كان $5.5M مقابل دخل صافي قدره $0.9M في الربع الثالث 2024. EBITDA المعدّل كان $2.5M. الأصول النقدية والأوراق المالية القابلة للتداول بلغت $261.7M. توجيهات الإيرادات للسنة الكاملة 2025 أعيد تأكيدها عند $196M–$205M.
- Total revenue of $52.3M (+2% YoY)
- Installed base reached 3,456 instruments (+161 units in Q3)
- Total recurring revenue growth of 19% YoY
- Biotech/pharma/CRO revenue growth of 14% YoY
- Cash and marketable securities of $261.7M as of Sept 30, 2025
- GAAP gross margin declined to 53% from 56% (adjusted margin 55% vs 60%)
- Net loss of $5.5M in Q3 2025 vs net income $0.9M in Q3 2024
- Adjusted EBITDA decreased to $2.5M from $7.6M
- General and administrative expenses increased 47% due to litigation-related costs and a $0.7M write-off
Insights
Revenue modestly up but margins and profitability weakened; guidance reaffirmed, cash steady.
Cytek reported $52.3 million in third quarter revenue, a
Profitability deteriorated: GAAP gross profit fell to $27.6 million and gross margin compressed to
The outcome hinges on three points: ability to restore gross margins, control G&A/legal costs, and convert installed‑base and recurring revenue growth into sustained adjusted EBITDA. Key risks include ongoing EMEA softness and the litigation‑related expense trend. Watch the full‑year guidance reaffirmation of
FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025.
Recent Highlights
- Total revenue for the third quarter of 2025 was
$52.3 million , representing a2% increase compared to the third quarter of 2024 - Expanded to a total installed base of 3,456 Cytek instruments, adding 161 units in the third quarter of 2025
- Double-digit total revenue growth year-over-year in all regions, except EMEA
- Worldwide revenue from biotechnology, pharmaceutical and clinical research organization (“CRO”) customers grew
14% year-over-year - Total recurring revenue, comprised of service and reagent revenues, grew
19% compared to the third quarter of 2024 - Expanded European headquarters in Amsterdam, increasing footprint by more than
40% with a customer service and training center
“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we look ahead, our team remains sharply focused on expanding our global installed base, growing our recurring revenue streams and on profitability and cash generation. While we remain mindful of market conditions, we believe Cytek is well-positioned to deliver long-term value for all of our stakeholders through the strong and disciplined execution of our strategic priorities.”
Third Quarter 2025 Financial Results
Total revenue for the third quarter of 2025 was
GAAP gross profit was
Operating expenses were
Research and development expenses were
Sales and marketing expenses were
General and administrative expenses were
Loss from operations in the third quarter of 2025 was
Adjusted EBITDA in the third quarter of 2025 was
Cash and marketable securities totaled
2025 Outlook
Cytek Biosciences reaffirms its 2025 revenue guidance of full year 2025 revenue to be in the range of
Webcast Information
Cytek will host a conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Statement Regarding Use of Non-GAAP Financial Information
Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three-month period ended September 30, 2025 and September 30, 2024. Management believes that non-GAAP financial measures, including “Adjusted gross profit,” “Adjusted gross profit margin,” “Adjusted EBITDA,” and “Adjusted EBITDA excluding investment income,” referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Forward-Looking Statements
This press release and the related conference call, webcast and presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “contemplate,” “estimate,” “intend,” “potential,” “predict,” or “continue” or the negatives of these terms or variation of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding Cytek’s ability to expand its global installed base, grow its recurring revenue streams and deliver long-term value for all of its stakeholders; Cytek’s future profitability and cash generation; Cytek’s future financial performance, including its outlook for fiscal year 2025 and expectations for 2025 total revenue; Cytek’s business strategies, product, and operational plans and market opportunities, as well as any expectations or assumptions thereto; and any statements regarding current or future macroeconomic trends or events and the impact of those trends and events on Cytek and its financial performance. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the sections titled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2025 and in Cytek’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 to be filed with the SEC on or about the date hereof, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release and the related conference call, webcast and presentation are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s as of any date subsequent to the date of this press release. Information contained on, or that is reference or can be accessed through, our website does not constitute part of this document, and inclusions of any website addresses herein are inactive textual references only.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
| Cytek Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Loss (unaudited) | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| (In thousands, except share and per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue, net: | ||||||||||||||||
| Product | $ | 38,114 | $ | 39,544 | $ | 97,639 | $ | 108,242 | ||||||||
| Service | 14,179 | 11,956 | 41,713 | 34,735 | ||||||||||||
| Total revenue, net | 52,293 | 51,500 | 139,352 | 142,977 | ||||||||||||
| Cost of sales: | ||||||||||||||||
| Product | 17,728 | 17,490 | 48,178 | 50,044 | ||||||||||||
| Service | 7,014 | 5,005 | 19,599 | 15,479 | ||||||||||||
| Total cost of sales | 24,742 | 22,495 | 67,777 | 65,523 | ||||||||||||
| Gross profit | 27,551 | 29,005 | 71,575 | 77,454 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 8,956 | 9,882 | 27,506 | 29,679 | ||||||||||||
| Sales and marketing | 11,666 | 12,429 | 36,309 | 37,240 | ||||||||||||
| General and administrative | 16,121 | 10,942 | 42,550 | 34,044 | ||||||||||||
| Total operating expenses | 36,743 | 33,253 | 106,365 | 100,963 | ||||||||||||
| Loss from operations | (9,192 | ) | (4,248 | ) | (34,790 | ) | (23,509 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (494 | ) | (119 | ) | (1,199 | ) | (694 | ) | ||||||||
| Interest income | 573 | 1,433 | 1,636 | 4,208 | ||||||||||||
| Other income, net | 1,344 | 3,091 | 8,543 | 3,972 | ||||||||||||
| Total other income, net | 1,423 | 4,405 | 8,980 | 7,486 | ||||||||||||
| (Loss) income before income taxes | (7,769 | ) | 157 | (25,810 | ) | (16,023 | ) | |||||||||
| Benefit from income taxes | (2,291 | ) | (784 | ) | $ | (3,347 | ) | (360 | ) | |||||||
| Net (loss) income | $ | (5,478 | ) | $ | 941 | $ | (22,463 | ) | $ | (15,663 | ) | |||||
| Net (loss) income, basic and diluted | $ | (5,478 | ) | $ | 941 | $ | (22,463 | ) | $ | (15,663 | ) | |||||
| Net (loss) income per share, basic | $ | (0.04 | ) | $ | 0.01 | $ | (0.18 | ) | $ | (0.12 | ) | |||||
| Net (loss) income per share, diluted | $ | (0.04 | ) | $ | 0.01 | $ | (0.18 | ) | $ | (0.12 | ) | |||||
| Weighted-average shares used in calculating net (loss) income per share, basic | 127,547,859 | 131,003,744 | $ | 127,604,317 | $ | 131,121,301 | ||||||||||
| Weighted-average shares used in calculating net (loss) income per share, diluted | 127,547,859 | 132,785,552 | $ | 127,604,317 | $ | 131,121,301 | ||||||||||
| Comprehensive (loss) income: | ||||||||||||||||
| Net (loss) income | $ | (5,478 | ) | $ | 941 | $ | (22,463 | ) | $ | (15,663 | ) | |||||
| Foreign currency translation adjustment, net of tax | 741 | 101 | $ | 784 | 1,232 | |||||||||||
| Unrealized gain on marketable securities | 118 | 195 | $ | 20 | 144 | |||||||||||
| Net comprehensive (loss) income | $ | (4,619 | ) | $ | 1,237 | $ | (21,659 | ) | $ | (14,287 | ) | |||||
| Cytek Biosciences, Inc. Consolidated Balance Sheets | ||||||||
| (In thousands, except share and per share data) | September 30, 2025 | December 31, 2024 | ||||||
| (unaudited) | (audited) | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 93,281 | $ | 98,716 | ||||
| Restricted cash | — | 29 | ||||||
| Marketable securities | 168,453 | 179,145 | ||||||
| Trade accounts receivable, net | 56,632 | 60,588 | ||||||
| Inventories | 51,649 | 43,893 | ||||||
| Prepaid expenses and other current assets | 18,474 | 14,075 | ||||||
| Total current assets | $ | 388,489 | $ | 396,446 | ||||
| Deferred income tax assets, noncurrent | 38,393 | 33,374 | ||||||
| Property and equipment, net | 18,046 | 17,962 | ||||||
| Operating lease right-of-use assets | 11,158 | 10,168 | ||||||
| Goodwill | 16,698 | 16,663 | ||||||
| Intangible assets, net | 17,676 | 20,128 | ||||||
| Other noncurrent assets | 4,459 | 4,759 | ||||||
| Total assets | $ | 494,919 | $ | 499,500 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Trade accounts payable | 7,632 | $ | 5,529 | |||||
| Legal settlement liability, current | 2,177 | 1,705 | ||||||
| Accrued expenses | 20,233 | 21,443 | ||||||
| Other current liabilities | 16,426 | 13,494 | ||||||
| Deferred revenue, current | 28,739 | 25,492 | ||||||
| Total current liabilities | 75,207 | 67,663 | ||||||
| Legal settlement liability, noncurrent | 8,158 | 9,036 | ||||||
| Deferred revenue, noncurrent | 16,315 | 16,098 | ||||||
| Operating lease liability, noncurrent | 13,494 | 7,552 | ||||||
| Long term debt | 655 | 1,050 | ||||||
| Other noncurrent liabilities | 2,519 | 2,364 | ||||||
| Total liabilities | $ | 116,348 | $ | 103,763 | ||||
| Stockholders’ equity: | ||||||||
| Common stock, | 128 | 129 | ||||||
| Additional paid-in capital | 435,284 | 430,791 | ||||||
| Accumulated deficit | (57,662 | ) | (35,199 | ) | ||||
| Accumulated other comprehensive gain | 821 | 16 | ||||||
| Total stockholders’ equity | $ | 378,571 | $ | 395,737 | ||||
| Total liabilities and stockholders’ equity | $ | 494,919 | $ | 499,500 | ||||
| Cytek Biosciences, Inc. Reconciliation of GAAP to Non-GAAP Measures (Unaudited) | ||||||||
| (In thousands) | Three months ended | |||||||
| September 30, 2025 | September 30, 2024 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| GAAP Gross profit | $ | 27,551 | $ | 29,005 | ||||
| Stock based compensation | $ | 906 | $ | 1,154 | ||||
| Amortization of acquisition-related intangible assets | $ | 481 | $ | 492 | ||||
| Non-GAAP Adjusted gross profit | $ | 28,938 | $ | 30,651 | ||||
| GAAP Gross margin | 53 | % | 56 | % | ||||
| Non-GAAP Adjusted gross margin | 55 | % | 60 | % | ||||
| GAAP Net income | $ | (5,478 | ) | $ | 941 | |||
| Depreciation and amortization | $ | 3,063 | $ | 2,807 | ||||
| Provision for (benefit from) income taxes | $ | (2,291 | ) | $ | (784 | ) | ||
| Interest income | $ | (573 | ) | $ | (1,433 | ) | ||
| Interest expense | $ | 494 | $ | 119 | ||||
| Foreign currency exchange loss (gain) | $ | 886 | $ | (1,076 | ) | |||
| Stock based compensation | $ | 5,638 | $ | 7,053 | ||||
| Non-recurring deferred ATM facility offering cost write off | $ | 711 | $ | — | ||||
| Non-GAAP Adjusted EBITDA | $ | 2,450 | $ | 7,627 | ||||
| Investment income | $ | (1,960 | ) | $ | (1,914 | ) | ||
| Non-GAAP Adjusted EBITDA excluding investment income | $ | 490 | $ | 5,713 | ||||
FAQ
What were Cytek (CTKB) Q3 2025 revenues and year-over-year change?
How did Cytek's recurring revenue perform in Q3 2025 for CTKB?
What caused Cytek's higher operating expenses and G&A in Q3 2025 (CTKB)?
Did Cytek change its full-year 2025 revenue guidance for CTKB?
What was Cytek's cash position at the end of Q3 2025 for CTKB?
How did Cytek's profitability metrics change in Q3 2025 for CTKB?
